diagnost tool
guid line expect buy pt
deliv qualiti beat driven out-performance recur consum
help drive beat gross oper margin net incom also
announc acquisit marshfield lab posit key chang
model ad one-tim payment outgo ceo jon ayer
record strong busi usual reiter
buy rate rais pt ep
strong high qualiti beat rev rep organ
beat our/street y/i due stronger consum expect
high qualiti beat adj ep rep fxn beat
gm rep fxn beat help
beat consum product gain lab price gain om
rep fxn beat due revenu gm beat
result beat versu model assay grew vs
refer lab growth match us instrument growth
shi place sedivu slightli estim
acquir marshfield lab announc acquir marshfield lab wi-bas
lab compani lab rais us lab count marshfield
custom respons question call estim marshfield
gener rev identifi marshfield lab survey work
believ good bolt-on deal look cross-sel
custom bring modal ie poc test
increas sale forc plan add us-bas sale
forc rep add new smaller territori provid
servic rep support new territori rep shrink number clinic rep
call proven repeatedli strategi strong roi
help acceler growth increas servic custom retent
guid initi revenue guid rep
organ midpoint prior
street prior expect fx headwind
revenu guid adj ep rep cc y/i
vs prior report /street delta ep
guid street primarili due comp lower ep result
sever payment relat ceo transit confid upsid
initi guid magnitud like function new test launch
guid carri forward beat rais revenue guid
midpoint rep org
account impact ceo charg lower adj ep
guid rep fxn revenue
guid impli rev slightli prior benefit
one extra equiv busi day guid contempl one fewer monday
global leader anim health diagnost
instrument lab test softwar sell direct
global sale rep
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
model modestli rais revenu estim
primari reason relat ad rev relat marshfield lab think
like upsid estim lower ep estim larg carri
forward similar ep growth rate lower base year due charg
relat ceo chang hit
big pictur core compon buy thesi driven multi-year
opportun grow busi ou think intern anim health
diagnost market grow current size analyst day rais
anim diagnost revenu spend target billion compound-annual-growth-rate
billion led growth ou us think
could grow revenu faster year
underli pet practic growth remain solid disclos patient practic
data anim practic prepar help animalytix lead
anim health data firm call broke clinic visit growth total
visit growth note total visit grew vs
revis clinic visit grew
importantli total practic revenu grew healthi suggest us
visit bounc around quarter-to-quart practic revenu fairli
stabl rang year suggest stabl healthi end-us anim
near-term potenti growth driver includ limit
lack meaning competitor ou refer lab busi solid demand
lab test world-wide earli phase newer product launch integr
challeng zoetis/abaxi may allow execut even better near-
term traction new us ou sale rep push toward prevent
well test rather sickcar greater anim health dx util
result millennial-ag pet owner addit veterinarian
link takeaway compani analyst day last august
buy unchang target price octob
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price octob
diagnost tool
buy unchang target price octob
diagnost tool
